SPP 4040
Alternative Names: SPP-4040Latest Information Update: 01 Dec 2023
At a glance
- Originator Signpath Pharma
- Class Antiarrhythmics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Arrhythmias
Most Recent Events
- 07 Sep 2023 Pharmacodynamics data from a preclinical study in Arrhythmias released by Signpath Pharma (Signpath Pharma website, September 2023)
- 06 Sep 2023 Preclinical trials in Arrhythmias (Prevention) in USA (PO) prior to September 2023 (Signpath Pharma pipeline, September 2023)